The effect of folic acid fortification on plasma folate and total homocysteine concentrations

New England Journal of Medicine

Volumn 340, Issue 19, 1999, Pages 1449-1454

  Jacques, Paul F ^a   Selhub, Jacob ^a   Bostom, Andrew G ^b   Wilson, Peter W F ^c   Rosenberg, Irwin H ^a  

^a TUFTS UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; DIET SUPPLEMENTATION; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; FOOD ANALYSIS; GRAIN; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURAL TUBE DEFECT; NUTRITIONAL VALUE; PRIORITY JOURNAL;

EID: 0033551352     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199905133401901     Document Type: Article

References (42)

1. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996;61(44):8781-97.
2. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 1992;41(RR-14):1-7.
3. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-7.
4. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. BMJ 1993;306:1645-8.
5. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ 1981;282:1509-11.
6. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990;10:149-52.
7. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983;1:1027-31.
8. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257-61.
9. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260: 3141-5.
10. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989;262:2847-52.
11. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989;150:613-9.
12. Food standards: amendment of the standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1993;58(197): 53305-12.
13. Oakley GP Jr. Eat right and take a multivitamin. N Engl J Med 1998; 338:10601.
14. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
15. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health 1957;47:4-24.
16. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med 1975;4:518-25.
17. Araki A, Sako Y. Determination of free and total homocysteinc in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
18. Home DW, Patterson D. Loctobacillus casei microbiological assay of folic acid derivatives in 96-well microtiter plates. Clin Chem 1988;34:2357-9.
19. Tamura T, Freeberg LE, Cornwell PE. Inhibition by EDTA of growth of Lactobacillus casei in the folate microbiological assay and its reversal by added manganese or iron. Clin Chem 1990;36:1993.
20. Shin YS, Rasshofer R, Friedrich B, Endres W. Pyridoxal-5′-phosphate determination by a sensitive micromethod in human blood, urine and tissues: its relation to cystathioninuria in neuroblastoma and biliary atresia. Clin Chim Acta 1983;127:77-85.
21. Rimm ED, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 1992;135:1114-26.
22. 12. In: Shils ME, Olson JA, Shike M, eds. Modern nutrition in health and disease. 8th ed. Vol. 1. Philadelphia: Lea & Febiger, 1994:402-25.
23. SAS user's guide, version 6. Cary, N.C.: SAS Institute, 1989.
24. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-15.
25. 2]folic acid with three levels of total folate intake. FASEB J 1998;12:A511. abstract.
26. Hopkins PN, Wu LL, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vase Biol 1995;15:1314-20.
27. Schorah CJ, Devitt H, Lucock M, Dowell AC. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur J Clin Nutr 1988;52:407-11.
28. Afman L, Bagley P, Selhub J. Determination of folic acid in fortified cereal products using the affinity/HPLC method. FASEB J 1999;13:A891. abstract.
29. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid fortification of the food supply: potential benefits and risks for the elderly population. JAMA 1996;276:1879-85. [Erratum, JAMA 1997;277:714.]
30. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
31. Brattström LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid -an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
32. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988;37: 697-701.
33. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine lowering effect of folic acid. J Intern Med 1995;237:381-8.
34. Ubbink JB, Vermaak WJH, van der Merwe, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hypernomocysteinemia in humans. J Nutr 1994;124:1927-33.
35. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
36. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
37. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
38. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277:1775-81.
39. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
40. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-64.
41. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-59.
42. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893-6.